LEGN.O (LEGN.O) News
Follow LEGN.O (LEGN.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
FDA Clears Legend Biotech's LB2501 CAR — T Therapy for Clinical Trials
Legend Biotech received FDA clearance for its investigational new drug application for LB2501, a dual-targeting CD19/CD20 in vivo CAR-T therapy. The clearance supports a planned US Phase 1/2 trial in relapsed or refracto
REGULATION | Oct 15, 2026, 12:07 PM UTC
L
Legend Biotech says CARVYKTI posts about $710 million net trade sales in quarter ended Sept. 30, 2026
Legend Biotech flagged preliminary CARVYKTI net trade sales of about $710 million for the quarter ended Sept. 30, 2026. Figure was provided by partner Janssen; Legend Biotech has not independently verified the amount. No
EARNINGS | Oct 13, 2026, 11:35 AM UTC